Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Abercrombie & Fitch Co. (ANF) vs Invesco Ltd. (IVZ) Price & Performance

Abercrombie & Fitch Co.Trade
Invesco Ltd.Trade

Price performance (Past 24H)

Key statistics

Abercrombie & Fitch Co. vs Invesco Ltd. — how do they compare? Abercrombie & Fitch Co. trades at $113 (market cap $5.24B), while Invesco Ltd. trades at $31.45 (market cap $13.85B). The key difference: Invesco Ltd. is far larger — about 2.6× Abercrombie & Fitch Co.'s market cap, and Invesco Ltd. pays a 2.74% dividend while Abercrombie & Fitch Co. pays none. Which is the better fit depends on your goals.

ANFIVZ
Market Cap
$5.24B$13.85B
Sector
Consumer CyclicalFinancials
52-Week High
$129.85$32.01
52-Week Low
$65.61$20.67
Enterprise Value
$5.91B$24.01B
Dividend Yield
2.74%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Abercrombie & Fitch Co.

ANF trades at $113.06, down 4.61% on the day, but maintains strong fundamentals with a P/E of 11.41 and robust profitability margins. The stock exhibits a bullish technical trend with moving averages supporting upside, though oscillators signal overbought conditions. Recent earnings beats and a return to positive cash flow in 2026 highlight operational strength, while institutional interest grows, as seen with Amundi's increased stake in Q2 2026.

Outlook remains positive driven by earnings momentum and valuation appeal, but risks include Hollister brand headwinds and geopolitical tensions affecting EMEA growth. Analyst consensus leans bullish with a $112.86 price target, suggesting limited upside from current levels amid near-term volatility.

Invesco Ltd.

Invesco (IVZ) trades at $31.58, down 0.5% today but near its 52-week high, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, with Q3 results pending. Revenue has grown to $6.38 billion in 2025, though net income remains negative. Analyst consensus is a $32.50 price target with a mix of Buy and Hold ratings, and the firm maintains a stable dividend payout.

The outlook for IVZ is cautiously optimistic, supported by strong assets under management and positive cash flow trends. However, profitability challenges and expense pressures pose risks. Upside potential hinges on earnings improvement and market sentiment, while downside risks include margin compression and competitive pressures in asset management.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Abercrombie & Fitch Co.

Abercrombie & Fitch Co is a specialty retailer that sells casual clothing, personal-care products, and accessories for men, women, and children. It sells direct to consumer through its stores and websites, which include the Abercrombie & Fitch, Abercrombie kids, and Hollister brands. Most stores are in the United States, but the company does have many stores in Canada, Europe, and Asia. All stores are leased. Abercrombie ships to well over 100 countries via its websites. The company sources its merchandise from dozens of vendors that are primarily located in Asia and Central America. Abercrombie has two distribution centers in Ohio to support its North American operations. It uses third-party distributors for sales in Europe and Asia.

Read more on ANF

About Invesco Ltd.

Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).

Read more on IVZ